{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-260417","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2024-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.115215+00:00","generated_at":"2026-05-29T23:05:57.604544+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Intellia Phase 1 in vivo CRISPR therapy nex-z shows disease stabilization in ATTR amyloidosis","bullets":["Single dose of nex-z achieved mean 90% serum TTR reduction at month 12 in ATTR-CM (n=36); sustained >24 months.","81% of ATTR-CM patients stable/improved in NT-proBNP, 94% in hs-Troponin T at month 12; hospitalization rate 0.16/yr.","In ATTRv-PN, mean TTR reduction 91% at month 12 (n=33); neuropathy scores stable or improved through month 24.","Favorable safety: infusion-related reactions mild/moderate, no discontinuations; Phase 3 MAGNITUDE trials ongoing.","Data published in NEJM and presented at AHA 2024; supports hypothesis greater TTR reduction yields greater clinical benefit."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-260417","json":"https://secwatch.observer/filing/0001193125-24-260417.json","markdown":"https://secwatch.observer/filing/0001193125-24-260417.md","text":"https://secwatch.observer/filing/0001193125-24-260417.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000119312524260417/0001193125-24-260417-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000119312524260417/d828128d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T23:05:57.604544+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}